AbCellera's nonhormonal menopause drug shows early success Exciting clinical trial results, a new gene therapy moves forward, safety concerns, and more led the news this week. Brought to you byDDN editorial team

AbCellera's nonhormonal menopause drug shows early success Exciting clinical trial results, a new gene therapy moves forward, safety concerns, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/abcellera-s-nonhormonal-menopause-drug-shows-early-success-17430 On Monday, AbCellera announced exciting results from their Phase 2 study testing ABCL635, an investigational antibody targeting the neurokinin 3 receptor (NK3R), in women with menopause. The drug achieved best-in-class results for hot flashes, reducing the mean number per day down from 10 to 3.5, compared to 8.8 in the placebo group. The drug also resulted in improved sleep with no serious or severe adverse events. With this data so far pointing to a better efficacy and safety profile compared to the currently available Veozah from Astellas Pharma and Lynkuet from Bayer, AbCellera’s drug could soon be a lucrative addition to the market, providing a better option for many women. “If validated in Phase 3, ABCL635 could offer a new treatment option with a more convenient dosing regimen and potentially less toxicity,” said JoAnn Pinkerton, Professor of Obstetrics and Gynecology at the University of Virginia School of Medicine in the press release. – Allison Whitten